Epiphany Biosciences, Inc.

Wexford Capital LP is a hedge fund manager located in Greenwich, Connecticut. The firm was formed in February 2009 and is the successor to Wexford Capital LLC, formed in December 1995, and Wexford Management Corp., which was originally incorporated in May 1994. The firm serves as investment adviser, sub-adviser, manager or general partner with discretionary trading authority to private pooled investment vehicles, including U.S. limited partnerships and limited liability companies and non-U.S. corporations structured as hedge funds and private equity funds.

CDIB BioScience Venture Management targets mid- to late-stage, North American, European and Taiwanese life science and healthcare companies. Early stage investments are also is considered on a case-by-case basis. They are particularly interested in the fields of drug discovery, drug development, platform technologies, medical diagnostics, biopharmaceuticals, drug delivery and medical devices. Investments range from $2 million to $5 million. CDIB participates in private financings (including preferred stock, common stock and warrants/options) and in joint ventures and corporate partnerships.

Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipeline such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.